In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
Litt's app available free to subscribers - download for IOS and Android from the App Store or Google Play.
Adverse reactions attributed to entire drug class 'Immune checkpoint inhibitor (incl. programmed death receptor-1 (PD-1) inhibitor)'
Please login to view adverse reactions.
Bullous pemphigoid / pemphigoid
- (2024): Li JH+, Zhongguo Yi Xue Ke Xue Yuan Xue Bao 46(6), 872-882 (32 cases)
- (2022): Bur D+, J Am Acad Dermatol Aug, Online ahead of print (20 cases)
- (2022): Ingen-Housz-Oro S+, Melanoma Res Mar, Online ahead of print
- (2022): Schauer F+, Front Immunol Jul (e-Collection) (8 cases)
- (2021): Ogawa K+, Clin Drug Investig Jun, Online ahead of print [REVIEW]
- (2020): Molina GE+, Br J Dermatol Jun, Online ahead of print (15 cases)
- (2020): Morris LM+, J Cutan Pathol Mar, Epub ahead of print (2 cases)
- (2019): Fontecilla NM+, J Drugs Dermatol 18(1), 103 (1 case)
- (2019): Kosche C+, Dermatol Online J 25(10) (e-Collection) (1 case)
- (2019): Sadik CD+, Front Immunol 10, 1934 (1 case)
- (2018): Lopez AT+, Int J Dermatol Apr, Epub ahead of print [REVIEW]
- (2017): Bandino JP+, J Eur Acad Dermatol Venereol 31(8), e378
- (2016): Jour G+, J Cutan Pathol 43(8), 688 (5 cases)
- (2016): Naidoo J+, Cancer Immunol Res 4(5), 383 (3 cases)
Cutaneous adverse reaction (includes severe cutaneous adverse drug reaction (SCAR))
- (2023): L'Orphelin J-M+, J Eur Acad Dermatol Venereol Apr, Online ahead of print
- (2023): Martel J+, Hum Pathol May, Online ahead of print [REVIEW]
- (2023): Medri M+, Ital J Dermatol Venerol 158(6), 437-444
- (2022): Chen CH+, Curr Oncol 29(4), 2871-2886 [REVIEW]
- (2022): Juan-Carpena G+, Actas Dermosifiliogr 113(4), 376-387 [REVIEW]
- (2022): Salloum A+, Immunotherapy 14(6), 489-503 [REVIEW]
- (2020): Inoue S+, Gan To Kagaku Ryoho (Japanese) 47(8), 1189-1192 (9 cases)
Cutaneous toxicity / skin toxicity
- (2022): Nikolaou V+, Br J Dermatol Jul, Online ahead of print
- (2022): Yamamoto T, Clin Cosmet Investig Dermatol 15, 829-841 [REVIEW]
- (2018): Sibaud V+, Ann Dermatol Venereol (French) Apr, Epub ahead of print [REVIEW]
- (2018): Wang DY+, Cancer J 24(1), 36 [REVIEW]
- (2016): Spain L+, Cancer Treat Rev 44, 51 [REVIEW]
DRESS syndrome (Drug-induced hypersensitivity syndrome)
- (2023): Ingen-Housz-Oro S+, Melanoma Res Feb, Online ahead of print (13 cases)
Eczema / eczematous reaction / eczematous eruption
- (2016): Hwang SJ+, J Am Acad Dermatol 74(3), 45517%
- (2022): Taskaynatan H+, Melanoma Res Jun, Online ahead of print (3 cases)
Keratoacanthoma (Grzybowski syndrome)
- (2025): Mager L+, Arch Dermatol Res 317(1), 234 (19 cases) [REVIEW]
- (2017): Bandino JP+, J Eur Acad Dermatol Venereol 31(8), e378
Lichen planus (includes hypertrophic lichen planus)
- (2024): Meier-Schiesser B+, JAAD Int 15, 157-164
- (2016): Wakade DV+, Melanoma Res 26(4), 421 (3 cases)
Lichenoid eruption / lichenoid reaction
- (2020): Sethi M+, Dermatol Online J 26(12) (2 cases / female) (diagnosed as an inverse variant of lichenoid eruption)
- (2016): Hwang SJ+, J Am Acad Dermatol 74(3), 45517%
Lipodystrophy / acquired generalised lipodystrophy
- (2025): Riganti J+, JAMA Dermatol Apr, Online ahead of print
Lupus erythematosus (subacute cutaneous lupus erythematosus (SCLE))
- (2024): Wu Z+, Arch Dermatol Res 316(10), 722 (29 cases)
- (2017): Gauci ML+, Cancer Immunol Immunother 66(11), 1399 [REVIEW]
- (2024): Pach JJ+, Dermatol Clin 42(3), 481-493 [REVIEW]
- (2023): Mebarki S+, Bull Cancer Mar, Online ahead of print2%
- (2021): Halle BR+, J Immunother Cancer 9(10), e00306657% (exacerbation)
- (2016): Chia PL+, J Immunother 39(5), 202 (flare)
- (2023): Mebarki S+, Bull Cancer Mar, Online ahead of print14%
- (2019): Zhou H+, Front Pharmacol 10, e38715% (3% ≥ grade 3) [REVIEW]
- (2017): Gauci ML+, Cancer Immunol Immunother 66(11), 1399 [REVIEW]
- (2020): Khan S+, Oncologist Mar, Epub ahead of print (1 case) (with anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA4) therapy)
Sarcoidosis / sarcoid-like reaction (cutaneous sarcoidosis)
- (2020): Chorti E+, Eur J Cancer 131, 18 (10 cases) (drug-induced sarcoidosis-like reaction)
- (2019): Cohen Aubart F+, J Intern Med Oct, Epub ahead of print [REVIEW]
- (2023): Nicoletti MM+, Drugs Real World Outcomes Oct, Online ahead of print (70 reports)
- (2020): Terrier B+, Autoimmun Rev Aug (e-Collection)
Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN)
- (2024): Qin K+, J Inflamm Res 17, 7591-7605 [REVIEW]
- (2023): Satoh TK+, J Dermatol Nov, Online ahead of print [REVIEW]
- (2021): Zhu J+, EClinicalMedicine Jul (e-Collection) [REVIEW] (association)
- (2016): Goldinger SM+, Clin Cancer Res 22(16), 4023
Vasculitis (angiitis) / cutaneous vasculitis (angiitis)
- (2020): Kullberg SA+, Dermatol Online J 26(9) (e-Collection) (1 case / male)
- (2018): Daxini A+, Clin Rheumatol 37(9), 2579-2584 [REVIEW]
- (2023): Lo J+, Arch Dermatol Res Feb, Online ahead of print (151 cases)
- (2021): Lommerts JE+, Expert Opin Drug Saf Apr, Online ahead of print [REVIEW]
- (2019): Babai S+, Drug Saf Oct, Epub ahead of print [REVIEW]
- (2017): Gauci ML+, Cancer Immunol Immunother 66(11), 1399 [REVIEW]
- (2016): Hwang SJ+, J Am Acad Dermatol 74(3), 45515%
- (2020): Antoury L+, Dermatol Ther 33(6), e14171 (13 cases) [REVIEW]
- (2017): Rivera N+, JAMA Dermatol 153(11), 1162 (re-pigmentation)
- (2023): Mebarki S+, Bull Cancer Mar, Online ahead of print2%
- (2017): Vigarios E+, Support Care Cancer 25(5), 1713 [REVIEW]
- (2023): Vigarios E+, Ann Dermatol Venereol Mar, Online ahead of print [REVIEW]
Sicca syndrome / sicca symptoms (see also Sjögren‘s syndrome)
- (2024): Bitoun S+, Rheum Dis Clin North Am 50(2), 291-300 [REVIEW]
- (2022): Harris JA+, Oral Dis 28(8), 2083-2092 [REVIEW]
- (2020): Pringle S+, Clin Exp Rheumatol 38Suppl 126 (4), 253-260 [REVIEW]
- (2019): Warner BM+, Oncologist 24(9), 1259-1269
- (2023): Wong So J+, J Intern Med 294(1), 58-68 (47 cases) [REVIEW] (association)
- (2020): Umeda Y+, J Dermatol 47(11), 1322-1325
- (2024): Wang Y+, Front Cardiovasc Med Jun (e-Collection) (51 cases)
- (2024): Yamani N+, Cardiooncology 10(1), 37 [REVIEW]
- (2023): Ho CC+, J Chin Med Assoc 86(5), 499-505
- (2023): Li X+, Front Immunol Feb (e-Collection) [REVIEW]
- (2022): Ganesh S+, Front Cardiovasc Med Sep (e-Collection) [REVIEW]
- (2022): Zito C+, Cancers (Basel) 14(21), 5403 [REVIEW]
- (2021): Arangalage D+, Cancer Treat Rev Aug, Online ahead of print [REVIEW]
- (2021): Chen C+, Front Pharmacol Feb (e-Collection) [REVIEW]
- (2021): Dolladille C+, Eur Heart J Sep, Online ahead of print [REVIEW]
- (2018): Dong J+, Front Cardiovasc Med 5, 9 [REVIEW]
Cardiovascular adverse effect (includes major adverse cardiovascular events (MACE))
- (2024): Eldani C+, Front Oncol Jul (e-Collection) (grade 3–4)
- (2024): Nielsen DL+, JAMA Oncol Aug, Online ahead of print [REVIEW]
- (2022): Wu S+, Front Cardiovasc Med Aug (e-Collection) [REVIEW]
- (2021): Faron A+, Radiology Sep, Online ahead of print
- (2020): Khunger A+, Curr Oncol Rep 22(7), 65 [REVIEW]
Large-vessel vasculitis (includes giant cell arteritis)
- (2025): Cottu A+, Rheumatology (Oxford) Mar, Online ahead of print (27 cases)
- (2024): Hysa E+, Autoimmun Rev Aug, Online ahead of print [REVIEW]
- (2020): Henderson D+, BMJ Case Rep 13(5), e233496 (1 case)
- (2024): Tomsitz D+, Eur J Cancer Dec, Online ahead of print
- (2023): Coustal C+, J Immunother Cancer 11(5), e004792 (29 cases)
- (2023): Gao J+, J Leukoc Biol May, Online ahead of print (multiomics)
- (2023): Moradi A+, Cureus 15(7), e42071 [REVIEW]
- (2022): Cadour F+, Radiology Mar, Online ahead of print (41 cases)
- (2022): Deharo F+, J Clin Med 11(19), 5611 (3 cases)
- (2022): Longinow J+, Cancer Med Sep, Online ahead of print (11 cases) (with myasthenia gravis, myositis and myocarditis overlap syndrome)
- (2022): Thuny F+, JACC CardioOncol 4(5), 624-628 [REVIEW]
- (2022): Vasbinder A+, JACC CardioOncol 4(5), 689-700 [REVIEW]
- (2021): Esposito R+, Biomolecules 11(6), 785 [REVIEW]
- (2021): Matzen E+, Cardiooncology 7(1), 27 (87 cases) [REVIEW]
- (2021): Thuny F+, JACC CardioOncol 3(1), 157-161 [REVIEW]
- (2020): Balanescu DV+, Cardiovasc Pathol 47, 107211 (3 cases)
- (2020): Cautela J+, J Immunother Cancer 8(2), e001887 [REVIEW]
- (2018): Mahmood SS+, J Am Coll Cardiol 71(16), 1755 (35 cases)
- (2018): Tajiri K+, Jpn J Clin Oncol 48(1), 7 [REVIEW]
- (2017): Wang DY+, Curr Cardiol Rep 19(3), 21 [REVIEW]
- (2016): Johnson DB+, N Engl J Med 375(18), 1749 (fatal / 2 cases)
Myocarditis, myositis and myasthenia gravis overlap syndrome (Triple-M Syndrome)
- (2023): Longinow J+, Cancer Med 12(3), 2281-2289 (11 cases)
- (2021): Lipe DN+, Am J Emerg Med 46, 51-55 (7 cases)
- (2021): Pathak R+, Oncologist 26(12), 1052-1061 (60 cases) [REVIEW]
- (2023): Trontzas IP+, Cancers (Basel) 15(9), 2637 (17 cases) [REVIEW]
- (2019): Ederhy S+, Eur J Heart Fail 21(7), 945-947 [REVIEW]
- (2022): Alghamdi EA+, Saudi Pharm J 30(8), 1193-1199 (possible association)
- (2022): Liu T+, Curr Pharm Des Sep, Online ahead of print [REVIEW]
- (2022): McCrae KR+, Thromb Res 213(Suppl 1), S51-S57 [REVIEW]
- (2022): Sheng IY+, Target Oncol 17(5), 563-5699%
- (2023): Zhu J+, Int Immunopharmacol Nov, Online ahead of print (association)
- (2021): Urban H+, Front Immunol Jan (e-Collection) (12 cases)
- (2020): Oliveira MCB+, Front Neurol Dec (e-Collection) (23 cases) [REVIEW]
- (2022): Müller-Jensen L+, Eur J Cancer 175, 224-235 (30 cases)
- (2022): Müller-Jensen L+, Data Brief Dec (e-Collection) (30 cases)
- (2021): Velasco R+, JAMA Neurol Mar, Online ahead of print [REVIEW]
- (2019): Fujiwara S+, Intern Med Jun, Epub ahead of print (2 cases)
Fever (pyrexia) (includes hyperpyrexia)
- (2019): Zhou H+, Front Pharmacol 10, e38713% [REVIEW]
- (2020): Haugh AM+, Expert Opin Drug Saf 19(4), 479-488 [REVIEW]
- (2020): Okada K+, J Neurol Sep, Online ahead of print (36 cases) [REVIEW]
- (2019): McNeill CJ+, BMJ Case Rep 12(8), e229443 (1 case)
Neurological adverse effect / neurological deficit
- (2024): Eldani C+, Front Oncol Jul (e-Collection) (grade 3–4)
- (2024): Stavropoulou De Lorenzo S+, Biomedicines 12(6), 1319 [REVIEW]
Neurological adverse effect / neurological deficit
- (2024): Müller-Jensen L+, Data Brief Apr (e-Collection)
- (2022): Ruggiero R+, Front Oncol Mar (e-Collection)
- (2021): Cheng K+, Clin Med Insights Oncol Nov (e-Collection) [REVIEW]
- (2021): Mikami T+, J Neurooncol 152(1), 135-1447% [REVIEW]
- (2021): Plaçais L+, Brain Commun 3(4), fcab220 (40 cases)
- (2020): Haugh AM+, Expert Opin Drug Saf 19(4), 479-488 [REVIEW]
- (2020): Shi J+, Thorac Cancer 11(2), 481-487 [REVIEW]
- (2019): Möhn N+, J Clin Med 8(11)~1% [REVIEW]
- (2019): Pan PC+, Curr Oncol Rep 21(12), 108 [REVIEW]
- (2019): Sato K+, J Neurooncol 145(1), 1-9 [REVIEW]
- (2019): Shi J+, Zhongguo Fei Ai Za Zhi (Chinese) 22(10), 633-638 [REVIEW]
- (2023): Müller-Jensen L+, Neuro Oncol Oct, Online ahead of print (34 cases) (associated with subgroup-specific immune cell dysregulation)
- (2022): Villagrán-García M+, Neurol Sci Feb, Online ahead of print2–12% [REVIEW]
- (2021): Duong SL+, J Neurooncol Jan, Online ahead of print (18 cases)
Paraneoplastic neurological syndromes
- (2020): Mongay-Ochoa N+, J Neurol 267(7), 2154-2156 (2 cases) [REVIEW]
- (2019): Gill A+, J Neuroimmunol 334, 576980 (3 cases) (association)
- (2019): Vogrig A+, Neurol Neuroimmunol Neuroinflamm 6(6), e604 (6 cases) (induction / exacerbation)
Adrenal insufficiency (hypoadrenalism) / Addisonian crisis (includes Addison's disease)
- (2023): Xiang J+, Transl Oncol Sep, Online ahead of print (20 cases)
- (2022): Takayasu S+, Sci Rep 12(1), 12944%
- (2021): Iglesias P+, Pituitary Mar, Online ahead of print [REVIEW]
- (2021): Iglesias P+, Endocr Relat Cancer Oct, Online ahead of print
- (2020): Shi Y+, Endocr Pract Dec, Online ahead of print (15 cases)
Adrenocorticotropic hormone (corticotropin; ACTH) deficiency
- (2024): Yang L+, Clin Endocrinol (Oxf) May, Online ahead of print (12 cases)
- (2021): Iglesias P+, Pituitary 24(4), 630-643 (60 cases) [REVIEW]
Aspartate aminotransferase (AST) increased
- (2019): Chen C+, Oncoimmunology 8(5), e1581547 (≥ grade 3) [REVIEW]
- (2019): Wang BC+, Cancer Med Aug, Epub ahead of print2% (≥ grade 3) [REVIEW]
Autoimmune Polyendocrine Syndrome Type 2
- (2021): Zhao Z+, Cancer Immunol Immunother 70(6), 1527-1540 (23 cases) [REVIEW]
- (2020): Shi Y+, J Clin Endocrinol Metab 105(12), dgaa553 [REVIEW]
- (2022): Barnabei A+, Front Oncol Mar (e-Collection) [REVIEW]
- (2022): Barnabei A+, Front Endocrinol (Lausanne) Mar (e-Collection) [REVIEW]
- (2025): Zhan M+, Front Immunol Jan (e-Collection)
- (2024): Angelousi A+, Diseases 12(2), 40 (4 cases) (with concomitant medication)
- (2024): Chen J+, Endocrine Jul, Online ahead of print [REVIEW]
- (2024): Kani ER+, Endocrine Sep, Online ahead of print [REVIEW]
- (2024): Ruiz-Esteves KN+, JAMA Oncol Aug, Online ahead of print
- (2023): Cho YK+, Diabetes Metab J Jul, Online ahead of print [REVIEW]
- (2023): Liao D+, Int Immunopharmacol Jun, Online ahead of print [REVIEW]
- (2023): Marsiglio J+, Front Immunol Aug (e-Collection) (18 cases) (+/- chemotherapy)
- (2022): Liu J+, Transl Oncol Jul, Online ahead of print (171 cases) [REVIEW]
- (2021): Fischer M+, Harefuah (Hebrew) 160(10), 657-662 (2 cases) [REVIEW]
- (2021): Lo Preiato V+, Rev Endocr Metab Disord Jan, Online ahead of print [REVIEW]
- (2021): Muniz TP+, Cancers (Basel) 14(1), 89 (34 cases)
- (2021): Ogawa K+, Clin Drug Investig Jun, Online ahead of print [REVIEW]
- (2020): Quandt Z+, Clin Exp Immunol 200(2), 131-140 [REVIEW]
- (2020): Zhang R+, Chin Med J (Engl) Aug, Online ahead of print [REVIEW]
- (2020): Zheng Z+, Diabetes Metab Res Rev Jun, e3366 [REVIEW]
- (2019): Kotwal A+, BMJ Open Diabetes Res Care 7(1), e000591 [REVIEW]
- (2022): Zhang W+, Front Endocrinol (Lausanne) Jan (e-Collection) (9 cases) [REVIEW]
Endocrine-related adverse effect / endocrinopathy
- (2024): Ata F+, BMC Med 22(1), 58827%
- (2024): Elshafie O+, Endocrinol Diabetes Metab 7(4), e0050528%
- (2021): Deligiannis NG+, Medicina (B Aires) 81(2), 269-278 [REVIEW]
- (2020): Shi Y+, J Clin Endocrinol Metab Sep, Online ahead of print (30 cases) [REVIEW] (autoimmune polyendocrine syndrome type 2)
- (2021): Peiffert M+, Cancers (Basel) 13(8), 1944 (5 cases) [REVIEW]
- (2019): Brancatella A+, Eur Thyroid J 8(4), 192 (1 case)
Hyperglycemia (includes glucose increased)
- (2022): Zhang W+, Front Endocrinol (Lausanne) Jan (e-Collection) (9 cases) [REVIEW] (hyperosmolar hyperglycemia)
Hypertransaminasemia (hepatic transaminitis) / elevated transaminases
- (2021): Xu F+, Transl Lung Cancer Res 10(4), 1819-1828 (6 cases)
- (2020): Pu D+, Medicine (Baltimore) 99(5), e190133–17% (grade 3 or 4) [REVIEW]
- (2020): Yamamoto A+, J Cancer Res Clin Oncol Nov, Online ahead of print
- (2024): van der Leij S+, Front Endocrinol (Lausanne) Jul (e-Collection) (67 cases)
- (2023): Chen P+, J Clin Med 12(10), 3468 [REVIEW]
- (2023): Esteves-Ferreira S+, J Cancer Res Clin Oncol Mar, Online ahead of print
- (2023): Quandt Z+, J Endocr Soc Feb (e-Collection) [REVIEW]
- (2022): Jessel S+, Front Oncol Mar (e-Collection)
- (2020): du Payrat JA+, Bull Cancer (French) Mar, Epub ahead of print [REVIEW]
- (2020): Khan S+, Oncologist Mar, Epub ahead of print (1 case) (with anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA4) therapy )
- (2020): Kurokawa R+, AJNR Am J Neuroradiol Aug, Online ahead of print
- (2019): Albarel F+, Eur J Endocrinol 181(3), R107 [REVIEW]
- (2019): Di Dalmazi G+, Expert Rev Endocrinol Metab 14(6), 381 [REVIEW]
- (2019): Thapi S+, J Immunother Cancer 7(1), 248 (1 case)
- (2019): Wei KZ+, Melanoma Manag 6(1), eCollection MMT1312%
- (2016): Spain L+, Cancer Treat Rev 44, 51 [REVIEW]
- (2024): Iwamoto Y+, Cureus 16(10), e71699
- (2022): Yamada H+, BMC Endocr Disord 22(1), 110 (12 cases)
- (2019): Chen C+, Oncoimmunology 8(5), e1581547 (≥ grade 3) [REVIEW]
- (2022): Phillips AL+, Ann Pharmacother Feb, Online ahead of print19%
- (2020): Tian Z+, Cancer Manag Res 12, 133914% (with doxorubicin)
- (2019): Zhou H+, Front Pharmacol 10, e38714% [REVIEW]
- (2024): Brandlmaier M+, J Eur Acad Dermatol Venereol Nov, Online ahead of print14%
- (2024): Karaviti D+, Endocrine Feb, Online ahead of print [REVIEW]
- (2022): Patrizio A+, Curr Pharm Des May, Online ahead of print (10 cases)
- (2025): Wang A+, Endocrine Jan, Online ahead of print
- (2025): Yamauchi I+, Eur Thyroid J Jan, Online ahead of print [REVIEW]
- (2024): Wang Y+, Heliyon 10(5), e27077 [REVIEW]
- (2023): Albarel F+, Ann Endocrinol (Paris) Mar, Online ahead of print [REVIEW]
- (2022): Baek HS+, BMC Endocr Disord 22(1), 8934%
- (2021): Zhou N+, Lung Cancer 161, 34-41
- (2020): Pollack R+, J Clin Endocrinol Metab Jul, Online ahead of print39%
- (2020): Zhou Y+, Int Immunopharmacol Dec, Online ahead of print
- (2018): De Bruyne P+, Arch Dis Child 103(1), 78 (long-term use)
- (2017): Chalan P+, J Endocrinol Invest Dec, Epub ahead of print [REVIEW]
- (2016): Spain L+, Cancer Treat Rev 44, 51 [REVIEW]
- (2021): Abraham G+, Int J Cancer Nov, Online ahead of print2%
- (2017): Gauci ML+, Cancer Immunol Immunother 66(11), 1399 [REVIEW]
- (2023): Lee HJ+, Front Endocrinol (Lausanne) Apr (e-Collection) (124 cases)
- (2021): Brancatella A+, J Endocr Soc 5(9), bvab093 (20 cases)
- (2017): Collins M+, Ann Oncol 28(11), 2860
Celiac disease / coeliac disease
- (2020): Badran YR+, J Immunother Cancer 8(1), e000958 (8 cases) (association)
Cholangitis / sclerosing cholangitis
- (2021): Pi B+, Eur J Gastroenterol Hepatol Sep, Online ahead of print [REVIEW]
- (2020): Fujii M+, Clin J Gastroenterol Sep, Online ahead of print (1 case / male) (with chemotherapy)
- (2025): Kim TK+, Korean J Intern Med 40(1), 49-564%
- (2025): Pesch G+, Cancer Immunol Res Apr, Online ahead of print (pharmacogenomics)
- (2025): Zaher A+, Expert Opin Drug Saf Apr, Online ahead of print [REVIEW]
- (2024): Lenti MV+, ESMO Open Jul, Online ahead of print (96 cases)
- (2024): Zoghbi M+, Support Care Cancer 32(10), 680 [REVIEW]
- (2023): Desmedt V+, Eur J Cancer 187, 36-57 [REVIEW]
- (2023): Losurdo G+, Biomedicines 11(5), 1496 [REVIEW]
- (2023): Mebarki S+, Bull Cancer Mar, Online ahead of print5%
- (2023): Nakane T+, Kurume Med J Apr, Online ahead of print [REVIEW]
- (2023): Terrin M+, Int J Mol Sci 24(14), 11504 [REVIEW]
- (2022): Vaziri H+, J Clin Gastroenterol Apr, Online ahead of print [REVIEW]
- (2021): Farha N+, Clin Res Hepatol Gastroenterol Jul, Online ahead of print4%
- (2021): Ogawa K+, Clin Drug Investig Jun, Online ahead of print [REVIEW]
- (2021): Portenkirchner C+, Pharmaceuticals (Basel) 14(4), 367 [REVIEW]
- (2021): Yanai S+, Digestion Sep, Online ahead of print [REVIEW]
- (2020): Bellaguarda E+, Am J Gastroenterol Jan, Epub ahead of print [REVIEW]
- (2019): Abu-Sbeih H+, Curr Opin Gastroenterol Oct, Epub ahead of print [REVIEW]
- (2019): Chen C+, Oncoimmunology 8(5), e1581547 (≥ grade 3) [REVIEW]
- (2019): Delasos L+, Case Rep Oncol Med Jul, 2019:9069354 (1 case)
- (2019): Som A+, World J Clin Cases 7(4), 405 [REVIEW]
- (2019): Yanai S+, Dig Endosc Oct, Epub ahead of print (7 cases) [REVIEW]
- (2017): Collins M+, Ann Oncol 28(11), 2860
- (2016): Spain L+, Cancer Treat Rev 44, 51 [REVIEW]
- (2024): Zoghbi M+, Support Care Cancer 32(10), 680 [REVIEW]
- (2019): Abu-Sbeih H+, Curr Opin Gastroenterol Oct, Epub ahead of print [REVIEW]
- (2019): Yanai S+, Dig Endosc Oct, Epub ahead of print (11 cases) [REVIEW]
- (2017): Collins M+, Ann Oncol 28(11), 2860
- (2017): Gauci ML+, Cancer Immunol Immunother 66(11), 1399 [REVIEW]
- (2016): Spain L+, Cancer Treat Rev 44, 51 [REVIEW]
- (2020): Collins M+, Clin Gastroenterol Hepatol Jan, Epub ahead of print [REVIEW]
- (2020): Hayashi Y+, Dig Dis Sci Jul, Online ahead of print (8 cases)
- (2019): Alsaadi D+, J Immunother Cancer 7(1), 203 (1 case)
Gastritis / pangastritis / gastric irritation
- (2022): Sugiyama Y+, Endosc Int Open 10(7), E982-E989 (4 cases)
- (2020): Fujii M+, Clin J Gastroenterol Sep, Online ahead of print (1 case / male) (with chemotherapy)
Gastrointestinal adverse reaction
- (2024): Chornenkyy Y+, J Clin Pathol Sep, Online ahead of print
- (2023): Cheng Y+, Front Immunol Jun (e-Collection) [REVIEW]
- (2023): Zhang P+, Therap Adv Gastroenterol Apr (e-Collection) [REVIEW]
- (2021): Macovei Oprescu A+, Cureus 13(11), e19945 [REVIEW]
- (2023): Mebarki S+, Bull Cancer Mar, Online ahead of print2%
Gastrointestinal disorder / discomfort
- (2020): Sanz-Segura P+, Gastroenterol Hepatol (Spanish) Nov, Online ahead of print13%
Gastrointestinal perforation / perforated colon / gastric perforation
- (2020): Meserve J+, Aliment Pharmacol Ther Dec, Online ahead of print<5% [REVIEW]
Hepatic (liver) disorder / hepatobiliary disorder / hepatic (liver) dysfunction
- (2023): Yamada T+, Int J Clin Pharm Jan, Online ahead of print (with acetaminophen)
- (2022): Farshidpour M+, Middle East J Dig Dis 14(2), 244-253 [REVIEW]
- (2022): Liu Z+, Front Pharmacol Jan (e-Collection) [REVIEW]
- (2022): Miah A+, J Cancer Res Clin Oncol Sep, Online ahead of print6%
- (2021): Biewenga M+, Hepatol Int Feb, Online ahead of print2% (grade 3–4)
- (2020): Gauci ML+, Clin Res Hepatol Gastroenterol Aug, Online ahead of print6% (≥ grade 3)
- (2019): Chen C+, Oncoimmunology 8(5), e1581547 (≥ grade 3) [REVIEW]
- (2017): Gauci ML+, Cancer Immunol Immunother 66(11), 1399 [REVIEW]
- (2016): Spain L+, Cancer Treat Rev 44, 51 [REVIEW]
Hepatotoxicity / liver injury / acute liver injury / drug-induced liver injury (DILI)
- (2024): Ito T+, Hepatol Res Jun, Online ahead of print [REVIEW]
- (2024): Jiang Y+, Curr Oncol 31(11), 7129-714314% (7% ≥ grade 3) [REVIEW]
- (2024): Kawano M+, Diagnostics (Basel) 14(8), 815
- (2024): Yue M+, Int Immunopharmacol Mar, Online ahead of print [REVIEW]
- (2023): Atallah E+, JHEP Rep Oct (e-Collection) 9% (associated with combination therapy)
- (2023): Gudd CLC+, Semin Liver Dis 43(4), 402-417 [REVIEW]
- (2023): Hountondji L+, JHEP Rep Jun (e-Collection) (117 cases)
- (2023): Kobayashi T+, J Clin Transl Hepatol 11(5), 1239-1245 [REVIEW]
- (2022): Taherian M+, J Clin Transl Pathol 2(3), 83-90 [REVIEW]
- (2021): Ito T+, Hepatol Int Aug, Online ahead of print5% (≥ grade 3)
- (2020): Yamamoto A+, J Cancer Res Clin Oncol Nov, Online ahead of print
- (2017): Cramer P+, Curr Gastroenterol Rep 19(1), 3 [REVIEW]
- (2020): Sanz-Segura P+, Gastroenterol Hepatol (Spanish) Nov, Online ahead of print3%
- (2019): Zen Y+, Semin Diagn Pathol Jul, Epub ahead of print [REVIEW]
- (2020): Mizuno K+, J Gastroenterol Mar, Epub ahead of print5% (≥ grade 3)
- (2019): Imoto K+, Can J Gastroenterol Hepatol Dec (e-Collection) 15% (all-grade)
- (2017): Collins M+, Ann Oncol 28(11), 2860
- (2020): Porcu M+, Target Oncol Jan, Epub ahead of print [REVIEW]
Pancreatitis / acute pancreatitis
- (2025): Fang W+, Front Pharmacol Mar (e-Collection) [REVIEW] (pharmacovigilance / pharmacoepidemiology)
- (2025): Zhan M+, Expert Opin Drug Saf Apr, Online ahead of print1%
- (2023): Shirwaikar Thomas A+, Curr Gastroenterol Rep Oct, Online ahead of print [REVIEW]
- (2022): Sayed Ahmed A+, Curr Opin Gastroenterol Jul, Online ahead of print [REVIEW]
- (2025): Yasuda T+, Dig Liver Dis Jan (5 cases)
- (2023): Yamamoto T+, Invest New Drugs May, Online ahead of print (8 cases)
- (2020): Onoyama T+, World J Gastroenterol 26(3), 353-365 [REVIEW]
- (2017): Collins M+, Ann Oncol 28(11), 2860
Cystitis (includes interstitial cystitis / bladder pain syndrome)
- (2022): Li J+, Front Immunol Jan (e-Collection) [REVIEW]
- (2022): Li J+, Front Immunol Jan (e-Collection) [REVIEW]
- (2020): Tian Z+, Cancer Manag Res 12, 133919% (grade 3/4) (with doxorubicin)
- (2023): Guo Q+, Front Pharmacol Jan (e-Collection) (13 cases) [REVIEW] (case study analysis)
Eosinophilia / eosinophils increased
- (2025): Diamantopoulos PT+, Cancer Med 14 (7), e7067921%
- (2025): Lyu L+, Int J Cancer Mar, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
- (2022): Takayasu S+, Sci Rep 12(1), 1294 (association)
- (2020): Scanvion Q+, Oncoimmunology 9(1) (e-Collection) (37 cases)
- (2020): Omar NE+, Front Immunol 11, 1354 [REVIEW]
- (2019): Davis EJ+, Oncologist 24(5), 584-588 [REVIEW]
- (2019): Delanoy N+, Lancet Haematol 6(1), e48
Hemophagocytic lymphohistiocytosis
- (2019): Noseda R+, J Immunother Cancer 7(1), 117 (34 cases) [REVIEW]
- (2022): Moore DC+, Haemophilia Jul, Online ahead of print (12 reports) (association)
Neutropenia (neutrophils decreased)
- (2019): Zhou H+, Front Pharmacol 10, e3875% (≥ grade 3) [REVIEW]
Pancytopenia (includes bicytopenia)
- (2019): Cybulska-Stopa B+, Case Rep Oncol 12(3), 820 (1 case)
- (2019): Zhou H+, Front Pharmacol 10, e38714% [REVIEW]
- (2022): Guo Q+, Int Immunopharmacol Nov, Online ahead of print (55 cases) [REVIEW]
Thrombocytopenia / platelets decreased
- (2024): Moore DC+, Int Immunopharmacol Feb, Online ahead of print (pharmacovigilance)
- (2020): Liu X+, Front Oncol Dec (e-Collection) [REVIEW]
- (2023): Mebarki S+, Bull Cancer Mar, Online ahead of print7%
- (2022): Maeda A+, Rheumatology (Oxford) Sep, Online ahead of print14%
- (2024): Springer R+, Immunotherapy Jan, Online ahead of print
- (2019): Chen C+, Oncoimmunology 8(5), e1581547 (≥ grade 3) [REVIEW]
- (2019): Wang BC+, Cancer Med Aug, Epub ahead of print15% (≥ grade 3) [REVIEW]
- (2019): Zhou H+, Front Pharmacol 10, e38715% [REVIEW]
- (2025): Yoon JS+, Intern Med J Jan, Online ahead of print (20 cases)
- (2024): Ghosh N+, Rheum Dis Clin North Am 50(2), 325-335 [REVIEW]
- (2024): Gómez-Puerta JA+, Rheum Dis Clin North Am 50(2), 161-179 [REVIEW]
- (2024): Rose N+, Eur J Rheumatol Jan, Online ahead of print [REVIEW]
- (2024): Singh N+, Rheum Dis Clin North Am 50(2), 269-279 [REVIEW]
- (2022): Chan KK+, J Inflamm Res May (e-Collection) [REVIEW]
- (2022): Gómez-Puerta JA+, Front Med (Lausanne) Jun (e-Collection)
- (2022): Ghosh N+, Semin Arthritis Rheum Oct, Online ahead of print
- (2022): Jensen AK+, Biomed Pharmacother Feb, Online ahead of print [REVIEW]
- (2022): Kim ST+, Nat Commun 13(1), 1970 (20 cases)
- (2020): Angelopoulou F+, Rheumatol Int Aug, Online ahead of print58% [REVIEW]
- (2019): Braaten TJ+, Ann Rheum Dis Sep, Epub ahead of print
Musculoskeletal adverse effects
- (2023): Liu H+, Front Pharmacol Oct (e-Collection) (FDA Adverse Event Reporting System data)
Myalgia/Myositis/Myopathy/Myotoxicity
- (2024): Jayan A+, Rheum Dis Clin North Am 50(2), 281-290 [REVIEW]
- (2022): Longinow J+, Cancer Med Sep, Online ahead of print (11 cases) (with myasthenia gravis, myositis and myocarditis overlap syndrome)
- (2021): Pathak R+, Oncologist Aug, Online ahead of print [REVIEW]
- (2020): Angelopoulou F+, Rheumatol Int Aug, Online ahead of print14% [REVIEW]
- (2023): Masi G+, Ann Clin Transl Neurol Mar, Online ahead of print (5 cases)
- (2022): Longinow J+, Cancer Med Sep, Online ahead of print (11 cases) (with myasthenia gravis, myositis and myocarditis overlap syndrome)
- (2022): Marco C+, J Clin Med 12(1), 130 (6 cases)
- (2022): Niimura T+, J Clin Pharmacol Dec, Online ahead of print (age association)
- (2021): Ogawa K+, Clin Drug Investig Jun, Online ahead of print [REVIEW]
- (2021): Pathak R+, Oncologist Aug, Online ahead of print [REVIEW]
- (2020): Huang YT+, Front Neurol 11, 634 [REVIEW] (immune-related)
- (2020): Yao S+, Zhongguo Fei Ai Za Zhi (Chinese) Aug, Online ahead of print [REVIEW]
- (2019): Becquart O+, J Immunother Jun, Epub ahead of print [REVIEW]
- (2019): Lara MS+, Clin Lung Cancer Apr, Epub ahead of print (1 case)
- (2020): Daoussis D+, Rheumatology (Oxford) 59(5), 1041
- (2024): Hysa E+, Autoimmun Rev Aug, Online ahead of print [REVIEW]
- (2024): Liew DFL+, Rheum Dis Clin North Am 50(2), 255-267 [REVIEW]
- (2022): Ghosh N+, Semin Arthritis Rheum Oct, Online ahead of print
- (2020): Angelopoulou F+, Rheumatol Int Aug, Online ahead of print12% [REVIEW]
Psoriatic arthralgia / psoriatic arthritis
- (2020): Nigro O+, Immunotherapy Apr, Epub ahead of print (1 case)
- (2021): Urasaki T+, Immunotherapy Nov, Online ahead of print (2 cases)
- (2020): Bomze D+, Ocul Immunol Inflamm Aug, Online ahead of print [REVIEW]
- (2019): Fang T+, J Curr Ophthalmol 31(3), 319 [REVIEW]
- (2022): Chaudot F+, J Clin Med 11(17), 4993 [REVIEW]
- (2025): Dezard VA+, J Neuroophthalmol Apr, Online ahead of print (3 cases) [REVIEW]
Uveitis / anterior uveitis / posterior uveitis / panuveitis
- (2025): Ide N+, Anticancer Res 45(5), 2215-2223 (pharmacovigilance / pharmacoepidemiology)
- (2023): Thibault T+, Ophthalmology Oct, Online ahead of print (46 cases) (association)
- (2021): Dow ER+, Ocul Immunol Inflamm 29(1), 203-211 [REVIEW]
- (2020): Hu F+, Immunotherapy May, Online ahead of print [REVIEW] (class-specific ear toxicities detected)
- (2019): Lemasson J+, Eur J Cancer 117, 116 (4 cases)
Vestibular disorder / vestibulopathy
- (2020): Koch EAT+, J Immunother Dec, Online ahead of print (1 case / male)
Fanconi syndrome (proximal tubular dysfunction)
- (2020): Farid S+, Cureus 12(4), e7686 (1 case)
Nephritis / interstitial nephritis / tubulointerstitial nephritis
- (2024): Elghawy O+, J Oncol Pharm Pract May, Online ahead of print (12 cases)
- (2022): Abudayyeh A+, Cancers (Basel) 14(21), 5267 (35 cases)
- (2021): Draibe JB+, Clin Kidney J 14(3), 884-890 (13 cases)
- (2021): Gérard AO+, Cancer Immunol Immunother Jun, Online ahead of print (63 cases)
Nephrotoxicity / kidney injury / acute kidney injury (AKI) / drug-induced kidney injury
- (2024): Thomas AS+, Gastro Hep Adv 3(3), 361-367 (229 cases)
- (2023): Seethapathy H+, Immunol Rev Jul, Online ahead of print [REVIEW]
- (2022): Catalano M+, Front Med (Lausanne) Dec (e-Collection) [REVIEW]
- (2022): Gérard AO+, Clin Kidney J 15(10), 1881-1887 (suggested association with administration of fluindione, a non-steroidal anti-inflammatory drug, or a proton-pump inhibitor)
- (2022): Lv D+, Discov Med 33(170), 137-141 [REVIEW]
- (2022): Tian R+, Kidney Dis (Basel) 8(3), 190-201 [REVIEW]
- (2022): Verploegen MFA+, Kidney360 3(3), 524-529 (16 cases)
- (2020): Tinawi M+, Cureus 12(12), e12204 [REVIEW]
- (2025): Kanaji N+, J Pers Med 15(3), 11518% (fatal / 6 cases)
- (2025): Nakai S+, Respir Investig 63(3), 259-26410%
- (2024): Utsunomiya A+, Expert Opin Drug Saf Dec, Online ahead of print
- (2024): Yokoi M+, J Pharm Health Care Sci 10(1), 526%
- (2022): Camard M+, Respir Med Res Nov, Online ahead of print
- (2019): Nakanishi Y+, Respir Investig Jun, Epub ahead of print17% (pre-existing lung abnormalities a risk factor)
- (2017): Delaunay M+, Eur Respir J 50(2), Epub23%
- (2024): Matsukane R+, J Immunother Cancer 12(12), e01011410–20%
- (2023): Allen E+, Front Oncol Oct (e-Collection) (10 cases) (association with patients with pre-existing obstructive pulmonary disease)
- (2022): Yin J+, Front Immunol Apr (e-Collection) 3–5% [REVIEW] (non-small-cell lung cancer patients)
- (2021): Abraham G+, Int J Cancer Nov, Online ahead of print4%
- (2021): Naganuma K+, Chemotherapy Apr, Online ahead of print (grade 3 / 1 case)
- (2021): Sun Z+, Invest New Drugs Jan, Online ahead of print (19 cases)
- (2020): Sakamoto K+, Respir Investig Jul, Online ahead of print [REVIEW]
- (2020): Tian S+, Int J Radiat Oncol Biol Phys Jan, Epub ahead of print11% (grade 3) (with stereotactic body radiotherapy )
- (2020): Tian Z+, Cancer Manag Res 12, 133910% (with doxorubicin)
- (2020): Zhu S+, Front Oncol 10, 17853% [REVIEW]
- (2019): Chen C+, Oncoimmunology 8(5), e1581547 (≥ grade 3) [REVIEW]
- (2019): Zhou H+, Front Pharmacol 10, e3874% (≥ grade 3) [REVIEW]
- (2017): Delaunay M+, Eur Respir J 50(2), Epub16%
- (2017): Gauci ML+, Cancer Immunol Immunother 66(11), 1399 [REVIEW]
- (2017): Khunger M+, Chest 152(2), 271 [REVIEW]
- (2017): Zhang S+, Mol Cancer Ther 16(8), 1588 [REVIEW]
- (2016): Nishino M+, JAMA Oncol 2(12), 1607 [REVIEW]
- (2016): Tabchi S+, Curr Opin Oncol 28(4), 269 [REVIEW]
- (2024): Rolim I+, Virchows Arch Nov, Online ahead of print
- (2022): Cui C+, Front Oncol Aug (e-Collection) [REVIEW]
- (2020): Mitropoulou G+, Respiration Jan, Epub ahead of print (severe / 2 cases)
- (2024): Pak KY+, Ann Otol Rhinol Laryngol Aug, Online ahead of print [REVIEW]
Sinusitis (see also rhinitis / rhinosinusitis)
- (2024): Tzoumpa S+, Immunotherapy Sep, Online ahead of print (12 cases)
- (2017): Dein E+, J Immunother 40(8), 312-314
Adverse effects / adverse reactions
- (2025): Alwhaibi A+, J Clin Med 14(2), 388
- (2024): Miller S+, Lancet Oncol Nov, Online ahead of print
- (2024): Tan K+, Clin Transl Oncol Jun, Online ahead of print [REVIEW]
- (2024): Tyagi S+, Crit Rev Oncol Hematol May, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
- (2023): Elmakaty I+, Cancer Cell Int 23(1), 90 [REVIEW]
- (2023): Liao D+, Int Immunopharmacol Feb, Online ahead of print (with epidermal growth factor receptor (EGFR) / anaplastic lymphoma kinase (ALK) inhibitor)
- (2022): Wen Y+, Expert Rev Hematol Aug, Online ahead of print [REVIEW]
- (2022): Xu J+, Front Immunol Jan (e-Collection) [REVIEW] (with chemotherapy)
- (2021): Al Nuhait M+, Sci Prog 104(1) (e-Collection) [REVIEW]
- (2021): Paderi A+, Curr Oncol 28(5), 3259-3267 [REVIEW]
- (2021): Pala L+, Expert Opin Drug Saf Sep, Online ahead of print [REVIEW]
- (2021): Perdigoto AL+, Curr Opin Immunol 69, 29-38 [REVIEW]
- (2021): Qi Y+, Front Pharmacol Jun (e-Collection) 64% (13% severe)
- (2021): Tian Y+, Front Oncol May (e-Collection) [REVIEW]
- (2020): Allouchery M+, J Immunother Cancer 8(2), e001622
- (2020): Cutroneo PM+, Br J Clin Pharmacol Jun, Online ahead of print49% (serious) [REVIEW]
- (2020): Hommes JW+, Front Oncol Feb (e-Collection) [REVIEW]
- (2020): Wang BC+, Oral Oncol Mar, Epub ahead of print94% (20% ≥ grade 3) [REVIEW]
- (2020): Yamaguchi O+, Cancer Chemother Pharmacol Mar, Epub ahead of print
- (2019): Bjornhart B+, Acta Oncol May, Epub ahead of print24% (grade 3–5) (1 case grade 5)
- (2019): Fox B+, Clin Transl Oncol Jun, Epub ahead of print [REVIEW] (with other prescription drugs)
- (2019): Huang YF+, Front Oncol Oct (e-Collection) [REVIEW] (with chemotherapy)
- (2019): Ni X+, Clin Res Hepatol Gastroenterol Jun, Epub ahead of print12% ≥ grade 3 [REVIEW]
- (2019): Zhou H+, Front Pharmacol 10, e38774% (24% ≥ grade 3; fatal / 2 cases) [REVIEW]
- (2017): Hu YB+, Transl Lung Cancer Res 6(Suppl 1), S8 [REVIEW]
- (2017): Le Burel S+, Eur J Cancer 82, 34
- (2025): Kanaji N+, J Pers Med 15(3), 115 (6 cases)
- (2023): Guo Q+, Front Pharmacol Jan (e-Collection) (7 cases ) [REVIEW] (case study analysis)
- (2022): Jing X+, Immunotherapy Sep, Online ahead of print (4 cases)
- (2019): Zhou H+, Front Pharmacol 10, e387 (2 cases) [REVIEW]
- (2018): Wang DY+, JAMA Oncol 4(12), 1721-1728 [REVIEW]
- (2016): Johnson DB+, N Engl J Med 375(18), 1749 (2 cases)
Generalized edema (includes anasarca)
- (2023): Velev M+, Eur J Cancer Jan (e-Collection) (20 cases)
- (2025): Le J+, Hum Vaccin Immunother Feb (e-Collection) [REVIEW]
- (2025): Sun Y+, Curr Opin Immunol Apr, Online ahead of print [REVIEW]
- (2024): Guo AJ+, World J Clin Oncol 15(8), 1002-1020 [REVIEW]
- (2024): Jayathilaka B+, Br J Cancer Nov, Online ahead of print [REVIEW]
- (2024): Jayathilaka B+, Br J Cancer Dec, Online ahead of print (Correction)
- (2024): Jayathilaka B+, Crit Rev Oncol Hematol Dec, Online ahead of print [REVIEW]
- (2024): Pozzessere C+, Cancers (Basel) 16(14), 2585 [REVIEW]
- (2024): Riveiro-Barciela M+, Gastroenterol Hepatol Jan, Online ahead of print [REVIEW]
- (2023): Burnett DL+, Front Endocrinol (Lausanne) Oct (e-Collection) [REVIEW]
- (2023): Geng R+, Front Immunol Mar (e-Collection)
- (2023): Guérin C+, Bull Cancer May, Online ahead of print31% (≥ grade 2)
- (2023): Lou S+, Front Pharmacol Apr (e-Collection) 39%
- (2023): Velev M+, Eur J Cancer 179, 28-47
- (2022): Jing X+, Immunotherapy Sep, Online ahead of print (fatal / 4 cases)
- (2022): Storm BN+, J Geriatr Oncol Jun, Online ahead of print
- (2021): Abdayem P+, Expert Opin Drug Saf Jan, Online ahead of print [REVIEW]
- (2021): Husain B+, J Cancer Res Clin Oncol Apr, Online ahead of print
- (2021): Qi Y+, Front Pharmacol Jun (e-Collection) 15%
- (2021): Zhao Q+, Front Immunol Sep (e-Collection) [REVIEW]
- (2021): Zhao Z+, Target Oncol May, Online ahead of print9% (? grade 3) (+/- chemotherapy)
- (2020): Abou Alaiwi S+, J Immunother Cancer 8(1), e00014445%
- (2020): Allenbach Y+, Autoimmun Rev Jun, Online ahead of print [REVIEW] (rheumatic and musculoskeletal Immune-related adverse effects)
- (2020): Karimian Z+, BMC Cancer 20(1), 1128 [REVIEW]
- (2020): Qin Q+, Zhongguo Fei Ai Za Zhi (Chinese) Aug, Online ahead of print [REVIEW]
- (2020): Tang H+, Zhongguo Yi Xue Ke Xue Yuan Xue Bao (Chinese) 42(6), 825-830 [REVIEW] (biomarkers)
- (2020): Triggianese P+, Autoimmun Rev Jun, 102590 [REVIEW]
- (2019): Rambhia PH+, Int J Clin Oncol Jul, Epub ahead of print [REVIEW] (sarcoidosis-like granulomas)
- (2019): Tison A+, Arthritis Rheumatol Aug, Epub ahead of print
- (2019): Wei KZ+, Melanoma Manag 6(1), eCollection MMT1329%
